Feasibility Study of Metformin Therapy in ADPKD

• Status: Completed
• Trial end date: 2020-08-17
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to determine if treatment with metformin, a drug widely used for the treatment of diabetes type 2, is safe and well tolerated by individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who are not diabetic and who have slightly decreased kidney function. The study will also evaluate the effects of metformin on kidney growth and kidney function.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Autosomal Dominant Polycystic Kidney Disease and

• An estimated glomerular filtration (GFR) rate of 50-80 ml/min/1.73 m2;

• Subject is able to sign an Informed Consent

Exclusion Criteria:

• Diabetes mellitus,

• Active infection,

• Congestive heart failure,

• Liver disease,

• Alcohol or substance dependence,

• Cigarette smoking within the last 12 months;

• Females who are pregnant or breast feeding, or

• Are unwilling to use contraception;

• Are unable to undergo magnetic resonance imaging, or

• Have a contraindication to the use of metformin